Is the price fair?
What DHR's price assumes
Danaher Corporation trades at 38.3× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
38.3
Trailing P/E · Diagnostics & Research median 35.3 · 1.08× the median: the market pays up for this one
- Price / sales
- 5.21
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.4%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +7.5%
Growth the price implies · The price pays for +7.5% free cash flow growth a year for a decade; the business has delivered −9.0% a year over the last three.
Details›
- Price / book2026-Q1
- 2.44
- EV / EBIT2026-Q1
- 29.8
- EV / sales2026-Q1
- 5.73
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $5.47B
- Market capitalisation
- $125.4B
- 3-year revenue growth
- −0.45%
- 3-year free cash flow growth
- −9.0%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $139.49 |
| Its own P/E history, median | $180.97 |
| Its own P/E history, upper quartile | $197.16 |
| 52-week range | $161.91 – $241.54 |
| Today | $215.38 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #23 of 29 by Smart Score